Alluvi, formerly BI 4744, offers a significant development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://alluvipeptides359831.wikilowdown.com/user